INNO-LiPA® HLA-C

Detects all known alleles of HLA-C with one amplification and one strip

INNO-LiPA HLA-C is a line probe assay for the molecular typing of human leukocyte antigen (HLA) C alleles at allele group level (Cw*01 – Cw*18).

Please note that this product now only is available for sale in Spain and Italy. Contact us for more details.

INNO-LiPA HLA-C

Product number 80342

20 Tests
INNO-LiPA HLA-C Amplification

Product number 80343

20 Tests
CE marked
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Details
  • Conditions of sale
  • Citations
  • Documentation
  • Insights
  • Related products
  • Details

    Features & Benefits

    More informative than serology

    • INNO-LiPA HLA-C yields more information on genetic variation
    • New alleles mainly appear as new probe patterns, not blanks
    • Null alleles can be detected

    Convenient

    • Reagents are synthesized and are therefore not limited in quantity
    • Reagents are standardized to show minimal batch-to-batch differences
    • INNO-LiPA HLA-C utilizes DNA samples that are easy to transport
    • Cell viability or surface expression is not important
    • One strip replaces multiple testing

    Rapid

    • INNO-LiPA HLA-C can be used for large batch analysis
    • One technician – one to one hundred samples – one working day

    Simple

    • The LiPA technique is easy to perform
    • Automation is possible using TENDIGO and Auto-LiPA™ 48
    • Objective interpretation of data with LiRAS® for LiPA HLA software
  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Citations

    The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

  • Insights